공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 중증근무력증(MG) 치료제 시장(2020-2027년)

Global Myasthenia Gravis Therapeutics Market - 2021-2028

리서치사 DataM Intelligence
발행일 On Demand Report 상품 코드 974576
페이지 정보 영문 180 Pages
가격
US $ 4,350 ₩ 5,209,000 PDF & Excel (Single User License)
US $ 4,850 ₩ 5,807,000 PDF & Excel (Multiple User License)
US $ 7,850 ₩ 9,400,000 PDF & Excel (Enterprise License)


세계의 중증근무력증(MG) 치료제 시장(2020-2027년) Global Myasthenia Gravis Therapeutics Market - 2021-2028
발행일 : On Demand Report 페이지 정보 : 영문 180 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 중증근무력증(MG) 치료제 시장 성장은 면역요법 채용 증가, 유력한 의약품 승인, 생물학적 제제 대두, 희귀질환 인식 향상에 의해 지지되고 있습니다.

세계의 중증근무력증(MG) 치료제(Myasthenia Gravis Therapeutics) 시장에 대해 조사 분석했으며, 업계 분석, 부문별 시장 분석, 경쟁 상황, 주요 기업 등에 대한 체계적인 정보를 제공합니다.

목차

제1장 세계의 중증근무력증(MG) 치료제 시장 : 조사 방법과 범위

제2장 세계의 중증근무력증(MG) 치료제 시장 : 시장 정의와 개요

제3장 세계의 중증근무력증(MG) 치료제 시장 : 주요 요약

제4장 세계의 중증근무력증(MG) 치료제 시장 : 시장 역학

  • 시장에 영향을 미치는 요인
    • 성장 촉진요인
    • 성장 억제요인
    • 기회
    • 영향 분석

제5장 세계의 중증근무력증(MG) 치료제 시장 : 업계 분석

  • Porter's Five Forces 분석
  • 공급망 분석
  • 가격 분석
  • 규제 분석
  • 상환 분석
  • 미충족 수요

제6장 세계의 중증근무력증(MG) 치료제 시장 : COVID-19의 분석

  • 시장에 대한 COVID-19의 분석
  • COVID-19의 가격 동향
  • 수급 스펙트럼
  • 팬데믹 동안 시장과 관련된 정부 정책
  • 제조업체의 전략적 이니셔티브
  • 결론

제7장 세계의 중증근무력증(MG) 치료제 시장 : 종류별

  • 서론
  • 종류 부문별 시장 규모 분석·전년대비 성장률 분석
  • 종류 부문별 시장 매력 지수
    • 안구형
    • 선천성
    • 전신성
    • 일과성
    • 기타

제8장 세계의 중증근무력증(MG) 치료제 시장 : 치료별

  • 서론
  • 치료별 시장 규모 분석·전년대비 성장률 분석
  • 치료별 시장 매력 지수
    • 콜린에스테라아제 억제제
    • 면역억제제
    • 혈장분리교환법·정맥주사용 면역글로불린
    • 흉선절제술
    • 기타

제9장 세계의 중증근무력증(MG) 치료제 시장 : 최종사용자별

  • 서론
  • 최종사용자 부문별 시장 규모 분석·전년대비 성장률 분석
  • 최종사용자 부문별 시장 매력 지수
    • 병원
    • 클리닉
    • 기타

제10장 세계의 중증근무력증(MG) 치료제 시장 : 지역별

  • 서론
  • 지역별 시장 규모 분석·전년대비 성장률 분석
  • 지역별 시장 매력 지수
  • 북미
  • 유럽
  • 남미
  • 아시아태평양
  • 중동 및 아프리카

제11장 세계의 중증근무력증(MG) 치료제 시장 : 경쟁 상황

  • 경쟁 시나리오
  • 시장 포지셔닝/점유율 분석
  • M&A 분석

제12장 세계의 중증근무력증(MG) 치료제 시장 : 기업 개요

  • Alexion Pharmaceutical Inc.
  • Grifols SA
  • Avadel Pharmaceuticals plc.
  • Novartis AG
  • Pfizer, Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Bausch Health Companies Inc.
  • Shire plc. 등

제13장 세계의 중증근무력증(MG) 치료제 시장 : 주요 인사이트

제14장 세계의 중증근무력증(MG) 치료제 시장 : DataM

KSM 20.12.18

Market Overview

The global myasthenia gravis therapeutics market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Myasthenia gravis is a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. Muscles of the eyes, face, and swallowing are the most commonly affected muscles in the body. The weakening of these muscles can result in double vision, drooping eyelids, trouble talking, and trouble walking.

Market Dynamics

The global myasthenia gravis therapeutics market growth is driven by the rising adoption of immunotherapies, the approval of promising drugs, the emergence of biologics, and increasing awareness of rare diseases.

Rising in the number of myasthenia gravis cases is expected to drive the growth in the forecast period

According to the National Organization for Rare Disorders (NORD), in the U.S. around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders in general across the world.

Myasthenia gravis occurs more frequently in females than in males, and although symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and women during their 20s or 30s. There is no proven cure for myasthenia gravis, however, patients can be treated with medications and surgery for the management of the symptoms.

At present, research is focused on a better understanding of the specifics of the autoimmune problems associated with myasthenia gravis and improving their diagnosis and treatment. Additionally, the market is observing a paradigm shift in the area of research from suppressing the immune system to rebalancing it. Another important area of research is the physiology of the neuromuscular junction (NMJ), aimed at improvement in its function regardless of probable immune system attacks. These factor is driving the growth of the market in the forecast period.

Prevalence of autoimmune disorder expected to drive the market growth

Autoimmune disorder is a condition of immune system in which the body's immune system attacks healthy cells. It is most common in the older men (over 60) and young adult women (under 40). For instance, according to Cancer Facts & Figures 2019, estimated number of older adults age 85 years and above was 6.4 million in 2016 and it is expected to reach 19.0 million by 2060.

Myasthenia gravis (MG) is an autoimmune neuromuscular disorder that affects voluntary muscles. According to the Myasthenia Gravis Foundation of America, around 20 in 100,000 people in the U.S. are diagnosed with myasthenia gravis each year. Hence, increase in geriatric population is a key factor likely boost the growth of market.

Side effects of available products is likely to hinder the market growth

However, side effects associated with intravenous immunoglobulin (IVIG) preparations could present serious health problems in some patients. Some of the side effects associated with intravenous immunoglobulin (IVIG) are flushing, muscle cramps, chills, fever, nausea, vomiting, back/joint pain, chest pain, sudden cough, wheezing, or shortness of breath. These side effects can sometimes force a patient to discontinue the therapy and thus leading to restrain the market growth in the forecast period.

COVID-19 Impact Analysis

During the COVID-19 pandemic patients with autoimmune myasthenia gravis, might be at greater risk of worse outcomes than otherwise healthy people because of an immunocompromised state related to immunotherapy and possible respiratory and bulbar muscular weakness. However, cessation of immunotherapy in neuroinflammatory disorders has severe risks as well. Moreover, infections are a well recognised trigger of symptom exacerbation in patients with myasthenia gravis, and some drugs used in therapeutic trials early in the pandemic, including hydroxychloroquine and azithromycin, can provoke symptom exacerbations. COVID-19 associated risks and effects in Myasthenia Gravis (CARE-MG), is a joint effort of the International MG/COVID-19 Working Group and neurologists who help to take care of patients with myasthenia gravis globally and was formally launched in April 9, 2020. All these factors will drive the growth of the market in the forecast period.

Segment Analysis

Immunosuppressive drugs, segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

Immunosuppressant drugs are a class of drugs that suppress, or reduce, the strength of the body's immune system. Some of these drugs are used to make the body less likely to reject a transplanted organ, such as a liver, heart, or kidney. With the rise in the number of organ transplants and growing prevalence of autoimmune diseases worldwide, the global immunosuppressive drugs market is likely to gather momentum in the forecast period. There has been a substantial rise in the number of organ transplants in the recent years. Transplants for various organs such as pancreas, liver, kidneys, and lungs are on the rise thereby supporting the growth opportunities for the global immunosuppressive drugs market. According to the findings of World Health Organization (WHO), nearly 91,800 kidney transplant procedures, around 6,200 lung transplants and about 30,800 liver transplants took place in 2018. Prominent companies of the world are making efforts to leverage rise in organ transplant procedures, which is likely to add to the growth of the market in the forecast period.

Cholinesterase inhibitors is growing at a fast rate in the forecast period. For instance, Rozanolixizumab (UCB7665) is a humanized anti-human neonatal Fc receptor (FcRn) monoclonal antibody designed to reduce the levels of pathogenic IgG in autoimmune diseases. It is in clinical trial phase for reducing the levels of pathogenic IgG in autoimmune diseases and myasthenia gravis. Strong pipeline and introduction of new therapies are the factors likely boost the growth of myasthenia gravis market.

Geographical Analysis

North America region holds the largest market share global myasthenia gravis therapeutics market

North America expected to hold a major market share in the global myasthenia gravis therapeutics market. According to Myasthenia Gravis Foundation of America 2019 data, the prevalence of myasthenia gravis in the United States is estimated at 14 to 20 per 100,000 population, which approximately translates to 36,000 to 60,000 cases in the United States. However, the report states that myasthenia gravis may be underdiagnosed in many cases and the prevalence might be higher. Report also suggests that women are more often affected than men. The most common age at onset is the 20s and 30s in women and the 60s and 70s in men.

However, the developed North American countries like the US and Canada have well-structured and development healthcare systems. These countries also promote research and development for rare diseases and hence have very high expenditure on healthcare. As a result of these policies, many companies globally are encouraged to operate in this region.

Moreover, most of the population in developed countries like the US and Canada are covered under medical and health insurance and hence, are able to afford the expensive medication and therapies for myasthenia gravis. Hence, the North American region is expected to cover a large market share of the myasthenia gravis market.

Competitive Landscape

The myasthenia gravis therapeutics market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc. Novartis AG, Pfizer, Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Bausch Health Companies Inc., and Shire plc. Alexion Pharmaceuticals and Astellas Pharma among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the myasthenia gravis therapeutics market globally.

Key Companies to Watch

Pfizer Inc.

Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.

Product Portfolio: The Company's portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.

Why Purchase the Report?

  • Visualize the composition of the myasthenia gravis therapeutics market segmentation by type, treatment, end-use, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in myasthenia gravis therapeutics market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of myasthenia gravis therapeutics market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global myasthenia gravis therapeutics market report would provide an access to an approx. 45 + market data table, 40+ figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Myasthenia Gravis Therapeutics Market - By Type

  • Ocular myasthenia gravis
  • Congenital myasthenia gravis
  • Generalized myasthenia gravis
  • Transient myasthenia gravis
  • Others

Global Myasthenia Gravis Therapeutics Market - By Treatment

  • Cholinesterase inhibitors
  • Immunosuppressive drugs
  • Plasmapheresis and intravenous immunoglobulin
  • Thymectomy
  • Other

Global Myasthenia Gravis Therapeutics Market -By End-user

  • Hospital
  • Clinics
  • Others

Global Myasthenia Gravis Therapeutics Market - By Region

  • North America
  • South America
  • Europe
  • Asia
  • Middle East & Africa

Table of Contents

1. Global Myasthenia Gravis Therapeutics Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Myasthenia Gravis Therapeutics Market - Market Definition and Overview

3. Global Myasthenia Gravis Therapeutics Market - Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market snippet by Treatment
  • 3.3. Market Snippet by End-user
  • 3.4. Market Snippet by Region

4. Global Myasthenia Gravis Therapeutics Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Incidence of Myasthenia Gravis
      • 4.1.1.2. Increasing Research and Development for Myasthenia Gravis
    • 4.1.2. Restraints:
      • 4.1.2.1. Adverse Effects associated with drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Myasthenia Gravis Therapeutics Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Myasthenia Gravis Therapeutics Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Myasthenia Gravis Therapeutics Market - By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Ocular myasthenia gravis*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Congenital myasthenia gravis
  • 7.4. Generalized myasthenia gravis
  • 7.5. Transient myasthenia gravis
  • 7.6. Others

8. Global Myasthenia Gravis Therapeutics Market - By Treatment

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 8.1.2. Market Attractiveness Index, By Treatment
  • 8.2. Cholinesterase inhibitors *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Immunosuppressive drugs
  • 8.4. Plasmapheresis and intravenous immunoglobulin
  • 8.5. Thymectomy
  • 8.6. Other

9. Global Myasthenia Gravis Therapeutics Market - By End-user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user Segment
    • 9.1.2. Market Attractiveness Index, By End-user Segment
  • 9.2. Hospital *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Clinics
  • 9.4. Others

10. Global Myasthenia Gravis Therapeutics Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user

11. Global Myasthenia Gravis Therapeutics Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of key companies to watch
  • 11.5. List of the company with disruptive technology
  • 11.6. List of start-up companies

12. Global Myasthenia Gravis Therapeutics Market- Company Profiles

  • 12.1. Alexion Pharmaceutical Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Grifols SA
  • 12.3. Avadel Pharmaceuticals plc.
  • 12.4. Novartis AG
  • 12.5. Pfizer, Inc.
  • 12.6. AbbVie Inc.
  • 12.7. F. Hoffmann-La Roche Ltd.
  • 12.8. GlaxoSmithKline plc
  • 12.9. Bausch Health Companies Inc.
  • 12.10. Shire plc.

LIST NOT EXHAUSTIVE

13. Global Myasthenia Gravis Therapeutics Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us
Back to Top
전화 문의
F A Q